Greenwich LifeSciences jumps on US FDA's 'fast track' tag for breast cancer therapy

** Shares of cancer therapy developer Greenwich LifeSciences GLSI.O up 26% at $13.86 premarket

** Co says its breast cancer therapy, GLSI-100, got U.S. FDA's "fast track" designation

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** The therapy is being tested in a late-stage trial for patients with HER2-positive breast cancer who have the HLA-A*02 genotype, and who finished standard treatment

** Earlier in the year, co said the therapy showed an increased immune response over time in patients with the cancer, in the study

** As of last close, stock down 2% YTD